Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1072 of 6351
-
Immunotherapy combo shows promise against rare throat cancer
Disease control CompletedThis phase II trial studies how well nivolumab and chemoradiotherapy works in treating patients with stage II-IVB nasopharyngeal cancer. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. Chemoradiotherapy is the combina…
Phase 2 • Sponsor: Sue Yom • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Parenting coaching shows promise in preventing postpartum depression
Prevention CompletedThe primary aim of this study is to determine if a behavioral intervention targeting maternal caregiving of young infants can increase infant sleep and reduce fuss/cry behavior, and thereby (1) reduce the incidence and/or severity of postpartum maternal depression and (2) improve…
Sponsor: Columbia University • Aim: Prevention
Last updated Jun 27, 2026 07:51 UTC
-
New blood test may spot liver cancer sooner in High-Risk patients
Diagnosis CompletedBrief Summary (Plain-Language Version - Compliant with ClinicalTrials.gov Guidelines) The goal of this observational study is to learn whether a blood test called methylated SEPT9 (mSEPT9) can help diagnose hepatocellular carcinoma (HCC), the most common type of liver cancer, in…
Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Could a common cold sore drug slow Alzheimer's? new study explores the link.
Disease control CompletedAnti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex (valacyclovir, 500mg oral tablet). Valacyclovir, titrated to 4 grams per day, repurposed to treat Alz…
Phase 2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New Vaccine-Immunotherapy cocktail shows promise in ovarian cancer trial
Disease control OngoingThis is a phase 2 study whose purpose is to see whether the combination of of pembrolizumab, DPX-Survivac vaccine and low-dose cyclophosphamide has anti-tumor activity in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. DPX-Survivac is an i…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 26, 2026 18:48 UTC
-
New combo therapy shows promise for rare leukemia patients
Disease control OngoingThis is a multi-center, open label, single arm, phase II trial of the oral BRAF inhibitor, vemurafenib, plus obinutuzumab in patients with previously untreated HCL. A Simon mini-max two-stage design will be employed to assess the efficacy of the combination treatment of vemurafen…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New 5-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowBackground: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a Triple-Drug combo save Women's hearts when arteries look clear?
Disease control OngoingThe Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation (PROBE design) …
Phase 4 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising combo targets tough leukemia
Disease control OngoingThis phase II trial studies how well low-intensity chemotherapy and ponatinib work in treating patients with Philadelphia chromosome-positive and/or BCR-ABL positive acute lymphoblastic leukemia that may have come back or is not responding to treatment. Drugs used in chemotherapy…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThe aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduc…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a diabetes drug boost immunotherapy in advanced melanoma?
Disease control OngoingThe purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.
Phase 1 • Sponsor: Yana Najjar • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Glow-in-the-dark dye helps surgeons spot hidden pancreatic cancer
Diagnosis Recruiting nowThis phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW…
Phase 1/2 • Sponsor: George Poultsides • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
New brain clot removal device shows promise in stroke study
Disease control CompletedThe primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the treatment of intracerebral hemorrhage (ICH).
Sponsor: Penumbra Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug bimekizumab shows promise in clearing psoriasis in phase 3 trial
Disease control CompletedPhase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo aims to control advanced lung cancer
Disease control OngoingThis phase Ib/II trial studies the side effects and best dose of trametinib when given together with pembrolizumab and to see how well they work in treating patients with non-small cell lung cancer that has come back and spread to other places in the body, cannot be removed by su…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo therapy shows promise for older AML patients
Disease control OngoingThis pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for ce…
Phase 2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Triple drug cocktail shows promise against tough lung cancer
Disease control OngoingThe main purpose of this study is to see if the combination of nivolumab, ipilimumab and nintedanib is effective in people with non- small cell lung cancer. Researchers also want to find out if the combination of nivolumab, ipilimumab and nintedanib is safe and tolerable.
Phase 1/2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Genetic clues could personalize breast cancer treatment
Disease control Stopped earlyThe purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and, in patients with a PIK3CA mutation, on second-line…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Combination therapy shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis phase II trial studies how well pembrolizumab and external beam radiation therapy work in treating patients with non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab,…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a simple education program stop the cycle of fractures in the elderly?
Prevention CompletedThis is a study on the effects of education on secondary fracture prevention in primary health care centers (PHCC) and referral from hospitals to these PHCC of patients with recent fragility fractures. The design is Cluster-randomized controlled study with two arms. 40 primary h…
Sponsor: Helena Salminen • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC